Literature DB >> 22139543

Efficacy of dual antiplatelet therapy combined with Naoxintong capsules [see text] following coronary microembolization induced by homologous microthrombi in rats.

Huan Wang1, Wen-juan Zhong, Ming-wei Huang, Xiao-ying Wu, Hui Chen.   

Abstract

OBJECTIVE: To evaluate the effificacy of dual antiplatelet therapy combined with Naoxintong Capsule ([see text], NXTC) in a rat model of coronary microembolization (CME).
METHODS: A total of 95 rats were randomly divided into 6 groups: control, sham-operation, CME model, NXTC, dual antiplatelet (clopidogrel and aspirin) intervention (DA), and NXTC combined with DA (NDA) groups. The complete data in 69 rats were obtained. The number of CME, myocardial apoptosis rate, bleeding time, clotting time, and adensosine diphosphate (ADP)-induced platelet aggregation were assessed.
RESULTS: Compared with the CME group, the number of CME and myocardial apoptosis rates were signifificantly decreased in the NXTC, DA, and NDA groups (P <0.01). Compared with other intervention groups, the number of CME and myocardial apoptosis rates were the least in the NDA group (P <0.01), and the incidence of surgical bleeding was the highest in the DA group (P <0.01). Compared with the CME group, ADP-induced maximum platelet aggregation rate was significantly inhibited in the NXTC, DA, and NDA groups (P <0.01), both bleeding time and clotting time were signifificantly increased in the NXTC, DA, and NDA groups (P <0.01), while the above parameters were the highest in the DA group (P <0.05).
CONCLUSION: The combination therapy of NXTC and DA enhanced the anti-CME effect of either therapy alone and reduced the risk of the DA therapy-associated bleeding, demonstrating an improved benefifit/ risk ratio in the rat model of CME.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22139543     DOI: 10.1007/s11655-011-0935-4

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  32 in total

1.  Abnormal coronary flow velocity reserve after coronary intervention is associated with cardiac marker elevation.

Authors:  J Herrmann; M Haude; A Lerman; R Schulz; L Volbracht; J Ge; A Schmermund; H Wieneke; C von Birgelen; H Eggebrecht; D Baumgart; G Heusch; R Erbel
Journal:  Circulation       Date:  2001-05-15       Impact factor: 29.690

2.  Guiding principles for research involving animals and human beings.

Authors: 
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2002-08       Impact factor: 3.619

Review 3.  Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern.

Authors:  Edoardo Camenzind; P Gabriel Steg; William Wijns
Journal:  Circulation       Date:  2007-03-07       Impact factor: 29.690

4.  Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study.

Authors:  Peter Wenaweser; Joost Daemen; Marcel Zwahlen; Ron van Domburg; Peter Jüni; Sophia Vaina; Gerrit Hellige; Keiichi Tsuchida; Cyrill Morger; Eric Boersma; Neville Kukreja; Bernhard Meier; Patrick W Serruys; Stephan Windecker
Journal:  J Am Coll Cardiol       Date:  2008-09-30       Impact factor: 24.094

5.  Incidence, correlates, and clinical impact of nuisance bleeding after antiplatelet therapy for patients with drug-eluting stents.

Authors:  Itsik Ben-Dor; Rebecca Torguson; Mickey Scheinowitz; Yanlin Li; Cedric Delhaye; Kohei Wakabayashi; Gabriel Maluenda; Asmir I Syed; Sara D Collins; Manuel A Gonzalez; Michael A Gaglia; Zhenyi Xue; Kimberly Kaneshige; Lowell F Satler; William O Suddath; Kenneth M Kent; Augusto D Pichard; Ron Waksman
Journal:  Am Heart J       Date:  2010-05       Impact factor: 4.749

Review 6.  Coronary microembolization.

Authors:  Andreas Skyschally; Kkirsten Leineweber; Petra Gres; Michael Haude; Raimund Erbel; Gerd Heusch
Journal:  Basic Res Cardiol       Date:  2006-09       Impact factor: 17.165

7.  Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement.

Authors:  D Sibbing; S Schulz; S Braun; T Morath; J Stegherr; J Mehilli; A Schömig; N von Beckerath; A Kastrati
Journal:  J Thromb Haemost       Date:  2009-11-28       Impact factor: 5.824

8.  A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.

Authors:  Gregg W Stone; Stephen G Ellis; David A Cox; James Hermiller; Charles O'Shaughnessy; James Tift Mann; Mark Turco; Ronald Caputo; Patrick Bergin; Joel Greenberg; Jeffrey J Popma; Mary E Russell
Journal:  N Engl J Med       Date:  2004-01-15       Impact factor: 91.245

9.  Blockade of NF-kappaB by pyrrolidine dithiocarbamate attenuates myocardial inflammatory response and ventricular dysfunction following coronary microembolization induced by homologous microthrombi in rats.

Authors:  Shumei Li; Shishun Zhong; Kai Zeng; Yukun Luo; Feilong Zhang; Xudong Sun; Lianglong Chen
Journal:  Basic Res Cardiol       Date:  2010-01       Impact factor: 17.165

10.  Danqi Piantang Jiaonang (DJ), a traditional Chinese medicine, in poststroke recovery.

Authors:  Christopher Chen; N Venketasubramanian; Robert N Gan; Caroline Lambert; David Picard; Bernard P L Chan; Edwin Chan; Marie G Bousser; Shi Xuemin
Journal:  Stroke       Date:  2009-01-22       Impact factor: 7.914

View more
  8 in total

1.  Comparison of Aspirin and Naoxintong Capsule () with Adjusted-Dose Warfarin in Elderly Patients with High-Risk of Non-Valvular Atrial Fibrillation and Genetic Variants of Vitamin K Epoxide Reductase.

Authors:  Huan Wang; Xiao-Kai Zhou; Li-Fan Zheng; Xiao-Ying Wu; Hui Chen
Journal:  Chin J Integr Med       Date:  2016-02-26       Impact factor: 1.978

2.  Pretreatment with a combination of ligustrazine and berberine improves cardiac function in rats with coronary microembolization.

Authors:  Ying Zhang; Xiao-juan Ma; Chun-yu Guo; Ming-ming Wang; Na Kou; Hua Qu; Hui-min Mao; Da-zhuo Shi
Journal:  Acta Pharmacol Sin       Date:  2016-02-29       Impact factor: 6.150

3.  Chinese Experts Consensus on Clinical Application of Naoxintong Capsule ().

Authors:  Liu Long-Tao
Journal:  Chin J Integr Med       Date:  2018-04-14       Impact factor: 1.978

4.  A randomized controlled trial of adjunctive Bunchang Naoxintong Capsule (步长脑心通胶囊) versus maintenance dose clopidogrel in patients with CYP2C19*2 polymorphism.

Authors:  Hui Chen; Xiao-Ying Wu; Hong-Xia Wu; Huan Wang
Journal:  Chin J Integr Med       Date:  2014-11-27       Impact factor: 1.978

5.  Effect of Danhong Injection Combined with Naoxintong Tablets on Prognosis and Inflammatory Factor Expression in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention.

Authors:  Yun Lv; Yaping Pan; Yan Gao; Jingqian Lu; Yi Li; Jie Bai; Jing Zhai
Journal:  Acta Cardiol Sin       Date:  2015-07       Impact factor: 2.672

6.  In Vitro Assessment of Cytochrome P450 2C19 Potential of Naoxintong.

Authors:  Hui Chen; Ya Zhang; Xiaoying Wu; Candong Li; Huan Wang
Journal:  Evid Based Complement Alternat Med       Date:  2012-02-16       Impact factor: 2.629

7.  Xueshuan Xinmaining Tablet Treats Blood Stasis through Regulating the Expression of F13a1, Car1, and Tbxa2r.

Authors:  Xiaotian Zhang; Chao Zhang; Jingying Sai; Fan Li; Jinping Liu; Yang Li; Fang Wang
Journal:  Evid Based Complement Alternat Med       Date:  2015-03-02       Impact factor: 2.629

8.  Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods.

Authors:  Huizi Ouyang; Jiayuan Shen; Xuhua Huang; Wenjuan Ma; Qi Jia; Guangzhe Yao; Zhidan Tang; Dandan Zhang; Mengjie Sun; John Teye Azietaku; Jia Hao; Xiumei Gao; Yanxu Chang; Jun He
Journal:  Evid Based Complement Alternat Med       Date:  2019-09-23       Impact factor: 2.629

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.